Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Vaccine Stocks Slide, Psychedelic Stocks Surge After RFK Jr. HHS Nomination

Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...

CMPS : 4.45 (-4.51%)
PSIL : 11.91 (-0.78%)
ATAI : 1.5200 (-4.40%)
AZN : 64.26 (+1.68%)
BVNRY : 8.9500 (-0.83%)
NVAX : 8.04 (-0.25%)
MRNA : 38.25 (+3.55%)
CYBN : 10.16 (-8.96%)
GSK : 33.70 (+1.05%)
PFE : 25.13 (+0.76%)
BNTX : 108.23 (+5.96%)
SNY : 47.98 (+0.42%)
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?

Moderna MRNA is set to report third-quarter 2024 earnings on Nov. 7, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $1.25 billion and a loss of $1.91 per share,...

MRK : 99.86 (+2.48%)
MRNA : 38.25 (+3.55%)
GSK : 33.70 (+1.05%)
PFE : 25.13 (+0.76%)
Gilead, MRK Report Data From Investigational Combination Study for HIV

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.Data showed...

MRK : 99.86 (+2.48%)
ALNY : 246.80 (-0.80%)
GILD : 89.76 (+1.27%)
GSK : 33.70 (+1.05%)
Sanofi Negotiating Exclusively With CD&R for Opella 50% Stake Sale

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in its consumer healthcare (CHC)...

JNJ : 155.50 (+1.56%)
GSK : 33.70 (+1.05%)
PFE : 25.13 (+0.76%)
SNY : 47.98 (+0.42%)
Moderna Stock Falls 20% in a Month: Time to Sell or Hold?

Despite giving the world one of the first and most widely used COVID-19 vaccines, shares of Moderna MRNA have lost significantly in the past couple of years due to declining sales amid low demand for the...

MRNA : 38.25 (+3.55%)
GSK : 33.70 (+1.05%)
PFE : 25.13 (+0.76%)
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals (Revised)

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps...

AZN : 64.26 (+1.68%)
REGN : 744.50 (+0.15%)
GSK : 33.70 (+1.05%)
SNY : 47.98 (+0.42%)
GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps...

AZN : 64.26 (+1.68%)
REGN : 744.50 (+0.15%)
GSK : 33.70 (+1.05%)
SNY : 47.98 (+0.42%)
2 Best Artificial Intelligence Stocks to Buy in October

These companies could have more growth ahead than investors realize.

NVDA : 146.67 (+0.53%)
AI : 34.99 (+8.13%)
GSK : 33.70 (+1.05%)
PLTR : 61.36 (-1.22%)
Gilead's HIV Prevention Treatment Lenacapavir Shows Potential

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, for the prevention...

GILD : 89.76 (+1.27%)
GSK : 33.70 (+1.05%)
PFE : 25.13 (+0.76%)
GSK Posts New Data From Phase III Study on RSV Vaccine Arexvy

GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV) vaccine,...

MRNA : 38.25 (+3.55%)
GSK : 33.70 (+1.05%)
PFE : 25.13 (+0.76%)

Barchart Exclusives

Up 99% in the Past Year, How High Can This Growth Stock Rise?
With Lumentum shares skyrocketing over the past year, can this growth stock keep climbing? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar